Phase 3 Clinical Trials With Primary Completion Dates in August 2018

This is a list of Phase 3 trials with primary completion dates in August 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AIMT Aimmune Therapeutics, Inc. 2018-08-01 Phase 3 NCT03126227 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children
ALKS Alkermes plc 2018-08-01 Phase 3 NCT02110264 Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
AQXP Aquinox Pharmaceuticals, Inc. 2018-08-01 Phase 3 NCT02858453 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
AVEO AVEO Pharmaceuticals, Inc. 2018-08-01 Phase 3 NCT02627963 A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
ENDP Endo International plc 2018-08-01 Phase 3 NCT03446781 Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
ENDP Endo International plc 2018-08-01 Phase 3 NCT03428750 Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
ESPR Esperion Therapeutics, Inc. 2018-08-01 Phase 3 NCT02991118 Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
FGEN FibroGen, Inc 2018-08-01 Phase 3 NCT02964936 A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia